Macroaxis: Personalized Investing
Personalized Investing and
Digital Wealth Optimization

GILD AMGN BIIB CELG Funds EUR Bitcoins Cleaning Cars 
Benchmark SP 500  1,650   2.23  Index Moved Down -0.14% United States ...


Processing
Collecting data for MDVN

Medivation quote and profile

 
 Companies |  Insiders  | Dashboard  
     
47.54
  
STOCK
(1.21)  Macroaxis: -2.48 Down   2.48%  
Year To Date
37.3359.24
Last 1 Month(s)
47.4152.05
Trading Day 
47.4748.89
June 19 2013 

Diversification Suggestion

Use Medivation to protect against small markets fluctuations. The stock experiences unexpected downward movement. The market is reacting to new fundamentals
Analyze Medivation Inc Trend or Check current 30 days Medivation correlation with market (S&P 500)
1 Month Beta 1.33  
Highest Price:  
Lowest Price:  
52.05  
47.41  
June 07 2013 
May 20 2013 
As market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, Medivation will likely underperform.
Medivation Inc Large BetaMedivation Inc Beta Legend
MDVN United States Nasdaq
Medivation Inc
Healthcare
Biotechnology
Benchmark S&P 500
http://www.medivation.com
Contact Number: 415. 543. 3470
Currency: USD - US Dollar
Traded on NASDAQ
    
Current Valuation3.49 B
Shares Outstanding74.98 M
Number of Shares Shorted3.41 M
Revenue191.02 M
 United States SP 500   0.14 % Macroaxis: 0.14 Moved Down  
 
 United States NYSE   0.19 % Macroaxis: 0.19 Moved Down  
 
 United States Russel   0.57 % Macroaxis: 0.57 Moved Down  
 
 thisRed MDVN MDVN agains markets  2.48 % Macroaxis: change 2.48 Moved Down  
 
Compare to Competition Alpha & Beta   Get Advice

Medivation Leadership

David Hung President CEO, Director
David MD CEO and President and Executive Director
Kim Blickenstaff Independent Chairman of the Board, MBA
Stephen Kelsey Senior Vice President - New Projects, Ph.D

Medivation Price and Market Media

The median price of Medivation for the period between Mon, May 20, 2013 and Wed, Jun 19, 2013 is 48.89 with a coefficient of variation of 2.75. The daily time series for the period is distributed with a sample standard deviation of 1.36, arithmetic mean of 49.4, and mean deviation of 1.1. The Stock received substential amount of media coverage during this period.
Medivation         SP 500
Price Growth (%)
 
Change Benchmark  Embed  Export  Timeline
1
Medivation Inc. Presents at UBS Global Healthcare Conference...05/21/2013Macroaxis: Seeking Alpha News
2
Medivation Inc. Presents at 38th Annual Deutsche Bank Health...05/30/2013Macroaxis: Seeking Alpha News
3
Canada Nod for Medivations Xtandi06/05/2013Macroaxis: News
4
Astellas Tecnofarma in Distribution Deal06/07/2013Macroaxis: News
5
Commit To Purchase Medivation At 33 Earn 12.606/12/2013Macroaxis: Forbes News

Medivation Summary

Medivation Inc [MDVN] is traded on NASDAQ in USA. It is located in Medivation, Inc.San Francisco, CA and employs 274 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 3.64 B. Medivation Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 74.98 M outstanding shares of which 3.41 M shares are now shorted by private and institutional investors with about 3.7 trading days to cover.
Medivation, Inc., a biopharmaceutical company, focuses on development and commercialization of novel therapies to treat serious diseases in the United States. more
Past Market
Over 30
Days
3
Out Of
100
 
Chance of
Less
Than
%
 
Follow Medivation with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Medivation to your reader
 

Medivation Research Report

Medivation vs. Gilead

Correlation analysis and fundamentals comparison between Medivation Inc and Gilead Sciences

Medivation Executives

C Machado CFO, Chief Business Officer
Patrick Machado CFO, Principal Accounting Officer and Chief Bus. Officer

Medivation Directors

Gregory Bailey Independent Director
Dawn Graham Director
Anne Bowdidge Sr. Director of Investor Relations
Wendy Yarno Independent Director
Daniel Adams Independent Director

Medivation Management

Cheryl Cohen Chief Commercial Officer

Medivation Fundamentals

Short Ratio vs Current Ratio
EBITDA vs Price to Sales
Short Ratio vs Shares Outstanding
Price to Book vs Price to Sales

Medivation vs Competition

Medivation vs. Gilead Sciences Inc
Medivation vs. Amgen Inc
Medivation vs. Biogen Idec Inc
Medivation vs. Celgene Corporation
Medivation vs. Regeneron Pharmaceuticals Inc
Medivation vs. Alexion Pharmaceuticals Inc
Medivation vs. Vertex Pharmaceuticals Incorporated
Medivation vs. BioMarin Pharmaceutical Inc
Medivation vs. Illumina Inc
Medivation vs. Onyx Pharmaceuticals Inc

Medivation June 19 2013 Opportunity Range

Downside Deviation3.29
Information Ratio0.0753
Maximum Drawdown13.25
Value At Risk(3.36)
Potential Upside2.83

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium